Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,232 recruiting studies in this area right now.
By phase
- Not applicable3,144
- Phase 21,064
- Phase 1822
- Phase 1/Phase 2446
- Phase 3425
- Phase 4238
- Phase 2/Phase 393
Top conditions
- Multiple Sclerosis344
- Multiple Myeloma334
- Asthma194
- Lymphoma183
- Rheumatoid Arthritis141
- Type 1 Diabetes131
- Atopic Dermatitis129
- Systemic Lupus Erythematosus126
- Acute Lymphoblastic Leukemia123
- HIV Infections117
- Chronic Lymphocytic Leukemia98
- Autoimmune Diseases81
- Follicular Lymphoma73
- Diabetes Mellitus, Type 170
- Hodgkin Lymphoma67
- Leukemia64
- Rheumatoid Arthritis (RA)64
- Mantle Cell Lymphoma62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)91
- National Cancer Institute (NCI)75
- Assistance Publique - Hôpitaux de Paris69
- Novartis Pharmaceuticals65
- M.D. Anderson Cancer Center62
- AstraZeneca57
- Mayo Clinic47
- City of Hope Medical Center46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama180
- Florida142
- Arizona140
- New York122
- Massachusetts120
- Texas118
- Illinois82
- Colorado77
Recruiting studies6,232 total
- NCT03738410Recruiting
Phone-based coaching to help women with HIV stay on track
This trial tests an mHealth (phone-based) program to help women with HIV improve health outcomes. It targets people who have had recent challenges with clinic visits, detectable virus levels, or taking HIV medicines.
Miami, FloridaAges 18 years+ - NCT07018323RecruitingPhase 2
Study of IMVT-1402 for Graves' disease
This trial tests an investigational drug called IMVT-1402 for people with Graves' disease whose thyroid is still overactive even while taking standard antithyroid medication. The goal is to see if the drug can better control thyroid hormone levels.
Tucson, ArizonaAges 18–75 - NCT07137598RecruitingPhase 2
A study of RO7790121 for moderate to severe rheumatoid arthritis
This study tests a new drug, RO7790121, for people with rheumatoid arthritis (RA) who have not gotten better with or could not tolerate common treatments like TNF inhibitors or JAK inhibitors. It aims to see if the drug is safe and can help reduce joint pain and swelling.
Peoria, ArizonaAges 18 years+ - NCT07287033RecruitingPhase 1
Safety study of MY006 in healthy people and people with peanut allergy
This early-phase study tests a new investigational medication (MY006) to see if it is safe and how the body processes it. It is given to both healthy volunteers and people with peanut allergy. The goal is to gather safety information before larger trials.
Little Rock, ArkansasAges 12–55 - NCT07360080Recruiting
Long-Term Effects of Teplizumab in Real-World Care
This study follows people who have already received teplizumab (a treatment to delay type 1 diabetes) to see how they do over time. It aims to understand the long-term effects in routine care.
Atlanta, GeorgiaAges Any age - NCT02402244Recruiting
Caring registry study for children and young people with cancer
This study keeps a careful record of children, teens, and young adults with cancer (and some related growths) and may follow them over time. It helps researchers better track outcomes and future contact so care can improve.
Birmingham, AlabamaAges Up to 25 years - NCT07421167RecruitingPhase 2
Ianalumab with TPO-RA for immune thrombocytopenia
This trial tests a new drug called ianalumab combined with a standard platelet-boosting medicine (TPO-RA) for adults with immune thrombocytopenia (ITP) or Evans syndrome. The goal is to see if the combination is well-tolerated and helps raise platelet counts.
Fayetteville, ArkansasAges 18 years+ - NCT06711146RecruitingEarly Phase 1
CAR T-cell therapy for active lupus
This study tests a new treatment using a type of immune cell therapy (CAR T-cells) for people with moderate to severe systemic lupus erythematosus (SLE) that has not responded well to standard treatments. The therapy aims to reset the immune system to reduce lupus activity.
Hangzhou, ZhejiangAges 18 years+ - NCT06210698Recruiting
Angioedema biomarker research study
This study collects blood samples (and optional skin samples) from people with angioedema to learn more about the condition and find better ways to diagnose and treat it. If you join, you may help scientists understand angioedema better.
Wheaton, MarylandAges 12–75 - NCT07780981Recruiting
Body position study for endoscopy pressure measurements
This study looks at whether lying on your back or side affects a measurement taken during a routine endoscopy procedure to check how well your esophagus and stomach opening are working. It may help doctors get more accurate readings to guide your care.
Baltimore, MarylandAges 5–21 - NCT00001465Recruiting
Study of lymphangioleiomyomatosis (LAM) disease process
This study looks at the natural history and disease process of lymphangioleiomyomatosis (LAM), a rare lung disease that mostly affects women. It may help understand how LAM progresses and how it affects daily life, and may include exercise testing and other evaluations.
Bethesda, MarylandAges 16–100 - NCT07783074Recruiting
Fatigue study using digital outcomes in multiple sclerosis and long COVID
This study is investigating fatigue using digital outcomes in people with multiple sclerosis, long COVID, and healthy volunteers. Participants must own a smartphone, be fluent in German or English, and be willing to provide informed consent. Exclusion criteria include having taken certain medications recently, being pregnant or lactating, or having additional health conditions that could affect fatigue or the autonomic nervous system.
Basel, BaselAges 18–65 - NCT07782944Recruiting
CD38 PET scan for multiple myeloma
This study uses a special PET scan that looks for a protein called CD38 on myeloma cells to see if it can better find and track multiple myeloma compared to the standard PET scan. It might help doctors plan your treatment more precisely.
Guilin, GuangxiAges 18 years+ - NCT06450925RecruitingPhase 2
Vitamin A supplement for stem cell transplant patients
This study tests whether giving vitamin A by mouth to adults before and after a stem cell transplant can help their recovery. The goal is to see if it reduces complications and improves overall outcomes.
Tampa, FloridaAges 18 years+ - NCT07187531RecruitingPhase 2
Testing a new drug to preserve insulin production in type 1 diabetes
This study tests a new drug called SAB-142, which aims to stop the immune system from attacking insulin-making cells in type 1 diabetes. It may help preserve your body's ability to make insulin. The trial will check if the drug is safe and effective.
San Francisco, CaliforniaAges 5–40 - NCT07003295RecruitingPhase 2
Glofitamab for mantle cell lymphoma that returned after CAR-T
This trial tests a new drug, glofitamab, for mantle cell lymphoma that came back or didn’t respond after CAR-T cell therapy. It aims to see if glofitamab can shrink or control the lymphoma.
Duarte, CaliforniaAges 18 years+ - NCT07683325RecruitingPhase 2
Study of ontunisertib for fibrostenosing Crohn's disease
This trial tests an investigational drug called ontunisertib versus a placebo in people with Crohn's disease that has caused narrowing (strictures) in the small intestine. It aims to see if the drug can help without needing surgery or other procedures.
Bradenton, FloridaAges 18 years+ - NCT07439653RecruitingPhase 1/Phase 2
Testing TORL-5-700 for advanced lymphoma
This trial tests a new treatment called TORL-5-700 for people with certain types of non-Hodgkin lymphoma that have not responded to other treatments. The goal is to see how safe it is and how well it works.
Fullerton, CaliforniaAges 18 years+ - NCT07002034RecruitingPhase 2
RE104 for adjustment disorder related to cancer or other serious illnesses
This trial is testing a new medication (RE104) for people who have adjustment disorder with depressed mood or anxiety because of a serious medical condition like cancer, ALS, MS, Parkinson's, or lung fibrosis. It's a study to see if the drug is safe and reduces symptoms.
Birmingham, AlabamaAges 18–80 - NCT06846671RecruitingPhase 3
Study of a new drug for CLL or SLL
This trial tests a new investigational drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already tried two types of treatments (BTK and BCL2 inhibitors). The goal is to see if this new drug works better than other available treatments chosen by the doctor.
Jonesboro, ArkansasAges 18 years+ - NCT07412704RecruitingPhase 1/Phase 2
Study of BMS-986528 for hard-to-treat rheumatoid arthritis
This trial tests a new drug called BMS-986528 for people with rheumatoid arthritis that is difficult to treat. It aims to see if the drug can help when other treatments haven't worked well.
La Jolla, CaliforniaAges 18–65 - NCT07053800RecruitingPhase 2
Obe-cel for severe lupus with kidney inflammation
This trial tests a new cell therapy called obe-cel in people ages 12 to 65 with severe systemic lupus erythematosus (SLE) that has not responded to other treatments and has caused active lupus nephritis (kidney disease). The goal is to see if obe-cel can reduce lupus activity and improve kidney health.
New York, New YorkAges 12–65 - NCT07305818RecruitingPhase 1
Testing a new drug for Graves' disease
This study tests a new medication called MER511 for adults with Graves' disease. The goal is to see if it is safe and how it works when taken once or multiple times.
Torrance, CaliforniaAges 18–65 - NCT05623020RecruitingPhase 3
New treatment for newly diagnosed transplant-ineligible myeloma
This Phase 3 study compares a three-drug combination (elranatamab, daratumumab, and lenalidomide) versus a standard three-drug treatment (daratumumab, bortezomib, lenalidomide, plus dexamethasone). It aims to see which plan works better for people newly diagnosed with multiple myeloma who cannot get a stem cell transplant.
Jupiter, FloridaAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,232 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,656 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.